Cargando…
10 Years of belimumab experience: What have we learnt?
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting both adults and children. Belimumab is the only biologic approved for SLE, and the first in a class of drugs known as B-lymphocyte stimulator-specific inhibitors. The introduction of intravenous belimumab in 20...
Autores principales: | Levy, Roger A, Gonzalez-Rivera, Tania, Khamashta, Munther, Fox, Norma Lynn, Jones-Leone, Angela, Rubin, Bernie, Burriss, Susan W, Gairy, Kerry, van Maurik, Andre, Roth, David A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564244/ https://www.ncbi.nlm.nih.gov/pubmed/34238087 http://dx.doi.org/10.1177/09612033211028653 |
Ejemplares similares
-
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
por: Sada, Kenei, et al.
Publicado: (2022) -
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
por: Petri, Michelle, et al.
Publicado: (2023) -
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022) -
Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
por: Sheikh, Saira Z., et al.
Publicado: (2016) -
Defining transposition: What have we learnt?
por: Roderick, Max E., et al.
Publicado: (2021)